Navigation Links
Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain
Date:10/31/2011

ccurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation.
  • Use NUCYNTA® ER with caution in patients with conditions accompanied by hypoxia, hypercapnia, or decreased respiratory reserve, such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression, or coma. In such patients, even usual therapeutic doses of NUCYNTA® ER may increase airway resistance and decrease respiratory drive to the point of apnea. Alternative non–mu-opioid agonist analgesics should be considered, and NUCYNTA® ER should be employed only under careful medical supervision at the lowest effective dose in such patients. If respiratory depression occurs, it should be treated as any mu-opioid agonist-induced respiratory depression.
  • Patients receiving other opioid agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, centrally acting muscle relaxants, or other CNS depressants (including alcohol) concomitantly with NUCYNTA® ER may exhibit additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, coma, or death may result if these drugs are taken in combination with NUCYNTA® ER. When such combined therapy is contemplated, a dose reduction of one or both agents should be considered.
  • Opioid analgesics can raise cerebrospinal fluid pressure as a result of respiratory depression with carbon dioxide retention. Therefore, NUCYNTA® ER should not be used in patients who may be susceptible to the effects of raised cerebrospinal fluid pressure, such as those with evidence of head injury and increased intracranial pressure. Opioid analgesics may obscure the clinical
    '/>"/>

  • SOURCE Janssen Pharmaceuticals Research & Development
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
    2. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
    3. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
    4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
    5. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
    6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
    7. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
    8. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
    9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
    10. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
    11. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... , Aug. 28, 2014 The Leukemia ... a partnership to advance an experimental cancer vaccine ... an asymptomatic stage of myeloma. The ... through which LLS forges collaborations with biotechnology companies ... OncoPep is developing a vaccine, PVX-410, ...
    (Date:8/28/2014)... ANTONIO , Aug. 28, 2014 GenSpera, ... for the treatment of cancer, announces the recent publication ... journal Steroids . The recent article ... reviews the evolution and development of GenSpera,s prodrug technology platform ... of thapsigargin (from the plant Thapsia garganica ) ...
    (Date:8/28/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) a leading ... for the eye, today announced that management will present at ... Palace Hotel on Wednesday, September 3 at 7:15 a.m. PT/10:15 ... CEO will offer a general overview of the Company,s current ... by Steve Brown , CFO, and Sam Gesten ...
    Breaking Medicine Technology:The Leukemia & Lymphoma Society Provides Equity Financing to OncoPep to Support Clinical Trial for Myeloma Vaccine 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3STAAR Surgical To Present At The Baird 2014 Health Care Conference 2
    ... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... of the largest network of radiotherapy and diagnostic imaging ... directors approved a share repurchase program, effective immediately. ... States federal securities laws, Concord Medical is authorized to ...
    ... Sept. 29, 2011 The Educational Review System held ... 28 at the Meyedenbauer Center in Bellevue, WA. Attendees ... pharmacy thought leaders discuss the challenges of pediatric medications, ... the 2010 recipient of the Institute for Safe Medication ...
    Cached Medicine Technology:Concord Medical Services Announces Share Repurchase Program 2Concord Medical Services Announces Share Repurchase Program 3
    (Date:8/28/2014)... be given to healthy volunteers in the UK, The ... of an series of safety trials of potential vaccines ... than 1,400 people in the current outbreak in West ... co-developed by the US National Institutes of Health (NIH) ... an international consortium in response to the Ebola epidemic, ...
    (Date:8/28/2014)... Catalent Pharma Solutions, the leading global ... for drugs, biologics and consumer health products, today ... Services, and Chris Greco, Manager, Comparator and Ancillary ... Active Control Clinical Trials” at the forthcoming US ... the 9th – 10th September, 2014 in Philadelphia, ...
    (Date:8/28/2014)... vaccine to prevent Ebola virus disease will begin next ... Diseases (NIAID), part of the National Institutes of Health. ... of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) ... to generate an immune system response in healthy adults. ... in Bethesda, Maryland. , The study is the first ...
    (Date:8/28/2014)... A subset of patients with stage III colon ... therapy, according to a new study in ... the American Gastroenterological Association. , When added to the ... irinotecan therapy improved overall survival rates for patients with ... in about 10 to 20 percent of colorectal cancers. ...
    (Date:8/28/2014)... over who identify themselves as ,old, feel worse about ... have lower value than younger age groups. , New ... ,Being old and ill, across different countries: social status, ... from the European Social Survey. Respondents, who were all ... health., The researchers found that those living in societies ...
    Breaking Medicine News(10 mins):Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Critical Path Sourcing Strategies for Global Clinical Trials Presented by Catalent Experts at US Clinical Trials Supply Conference 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:Drug shows promise for subset of stage III colon cancer patients 2
    ... ALEXANDRIA, Va., July 23 The model for,person-centered long ... to testimony submitted today to the US Senate Special ... care that embraces choice,independence and the opportunity for seniors ... Richard Grimes, the President and CEO,of the Assisted Living ...
    ... had heart trouble, the worse their performance , , WEDNESDAY, July ... heart disease seem to fare worse on measures of cognitive ... disease, the worse the performance in such mental processes as ... the July 23 issue of the European Heart Journal ...
    ... Three years after Hurricane Katrina devastated parts of the Gulf ... Public Health Project on the Public and Biological Security shows ... they are very prepared if a major hurricane were to ... worries of respondents threatened or hit by Hurricane Katrina are ...
    ... Cohen Hired As New CEO, ATLANTA, July 23 ... MELCO Investments LLC, a private business and,real estate investment ... a,substantial capital investment in GMCG. Along with the investment, ... leading colon and rectal,surgeons, as its new CEO., ...
    ... and Medicare Rules Highlighted; a Focus on Preventing ... Hospital-acquired Conditions, LANSING, ... a national leader in clinical risk management,practice and patient safety programs ... for its annual risk,management conference., The conference will take place ...
    ... the #1 Healthiest City to,Live and Retire In -, ... voice for 50+ Americans and the world,s largest-circulation,magazine with ... ten,healthiest cities to live and retire in with Ann ... Fargo, ND taking the top five rankings.,Featured in the ...
    Cached Medicine News:Health News:ASSISTED LIVING: The Model for Person-Centered Long Term Care 2Health News:Coronary Disease Dulls Cognitive Skills 2Health News:Hurricane preparedness survey: Worries about drinking water and medical care 2Health News:Hurricane preparedness survey: Worries about drinking water and medical care 3Health News:Hurricane preparedness survey: Worries about drinking water and medical care 4Health News:Hurricane preparedness survey: Worries about drinking water and medical care 5Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 2Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 3Health News:The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 3Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 4Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 5
    6 mm, 45 degree upwards, detachable....
    Aaron 950 is a high frequency desiccator with cut....
    The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
    The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
    Medicine Products: